ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference

28 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

26 авг 2023 10:00:00 Источник Nasdaq GlobeNewswire

Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023

11 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

08 авг 2023 15:15:00 Источник Nasdaq GlobeNewswire

Esperion Reports Second Quarter 2023 Financial Results

01 авг 2023 05:00:00 Источник Nasdaq GlobeNewswire

Esperion to Report Second Quarter 2023 Financial Results on August 1

17 июл 2023 05:00:00 Источник Nasdaq GlobeNewswire

Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023

07 июл 2023 07:00:00 Источник Nasdaq GlobeNewswire

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

28 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions

24 июн 2023 13:30:00 Источник Nasdaq GlobeNewswire

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023

15 июн 2023 13:30:00 Источник Nasdaq GlobeNewswire

Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023

08 июн 2023 07:00:00 Источник Nasdaq GlobeNewswire

Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023

05 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

01 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders

25 май 2023 15:30:00 Источник Nasdaq GlobeNewswire

Esperion to Participate in Jefferies Healthcare Conference

24 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

12 май 2023 15:30:00 Источник Nasdaq GlobeNewswire

Esperion Reports First Quarter 2023 Financial Results

09 май 2023 06:00:02 Источник Nasdaq GlobeNewswire

Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9

04 май 2023 07:30:00 Источник Nasdaq GlobeNewswire

Esperion to Participate in JMP Securities Life Sciences Conference

01 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

Esperion to Participate in Bank of America Securities 2023 Health Care Conference

27 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire